Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
MaxCyte is Featured Speaker at the Phacilitate Cell and Gene Therapy Forum 2007
January 16, 2007
Optimizing Production of Engineered Cell Therapies
Gaithersburg, Maryland - MaxCyteInc., a clinical stage therapeutic company and pioneer in clinical scale, non-viral cell loading systems, announces it will be a Co-Sponsor and featured speaker of the Phacilitate Cell and Gene Therapy Forum in Baltimore, Maryland.
Madhusudan V. Peshwa, Ph.D., Vice President Research and Development at MaxCyte, will be a featured speaker on Tuesday, January 23, 2007, at 11:55 AM. Dr. Peshwa's presentation entitled "Optimizing Production of Engineered Cell Therapies," will discuss producing sufficient product for effective therapy, developing a scalable process that reduces the regulatory risks and how cellular therapies can be manufactured in such a way to produce a consistent, reliable and uniform product.
MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include a Phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addition, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at CBER.